Royalty Pharma (RPRX) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viatris (VTRS) has outperformed Royalty Pharma (RPRX) over the past year, gaining 74.9% versus a gain of 56.1%. Over five years, RPRX leads with a +46.4% price change compared with +29.6% for VTRS. Royalty Pharma is the larger company by market cap ($32.48 billion vs $20.03 billion), about 1.6 times the size.
On valuation, Viatris trades at a lower forward P/E (6.5x vs 9.8x for Royalty Pharma). Viatris offers the higher dividend yield (2.75% vs 1.62%). Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RPRX | VTRS |
|---|---|---|
| Share price | $56.21 | $17.44 |
| Market cap | $32.48B | $20.03B |
| 1-day change | -0.97% | -0.29% |
| YTD return | +45.47% | +40.08% |
| 1-year return | +56.05% | +74.92% |
| 5-year return | +46.42% | +29.57% |
| P/E ratio (TTM) | 29.90 | — |
| Forward P/E | 9.80 | 6.52 |
| EPS (TTM) | $1.88 | $-0.36 |
| Dividend yield | 1.62% | 2.75% |
| Annual dividend | $0.91 | $0.48 |
| Revenue (latest FY) | $2.38B | $14.30B |
| Revenue growth (YoY) | +5.06% | -2.98% |
| Net income (latest FY) | $770.95M | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | 65.58% | -18.62% |
| Net margin | 32.42% | -24.58% |
| 52-week high | $64.38 | $18.43 |
| 52-week low | $35.23 | $9.69 |
| Distance from 52-week high | -12.69% | -5.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +16.31% | +12.96% |
| Average volume | 2.92M | 9.25M |
| Shares outstanding | 445.28M | 1.15B |
| Employees | 100 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed RPRX by 18.9 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.75% vs 1.62%).
- Royalty Pharma is more profitable, keeping 32.4 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Royalty Pharma grew revenue faster in its latest fiscal year (+5.06% vs -2.98%).
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
RPRX vs VTRS FAQ
Which is bigger, Royalty Pharma or Viatris?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.48B compared with $20.03B for Viatris (VTRS).
Which stock has performed better over the past year, RPRX or VTRS?
VTRS returned +74.92% over the past 12 months, compared with +56.05% for RPRX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Royalty Pharma or Viatris?
Viatris has the higher yield at 2.75%, compared with 1.62% for Royalty Pharma.
Are Royalty Pharma and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.